MEDS.PK together with its Russian licensee, ERCell LLC, successfully dosed 3 heart failure patients Read more…
KOOL has implemented a number of changes in corporate management responsibilities Read more…
MSB.AX’s off-the-shelf, allogeneic, Mesenchymal Precursor Cell (MPC) product for Type 2 diabetes … Read more…
Good morning! Here’s what you … might need to know to start the day. Read more…
End of Day, Cause and Effect Read more…
The 6 W’s: Who, what, where, when, why and what of it … Read more…
Juventas Therapeutics is a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease. Read more…
STEM announced the publication of preclinical data … Read more…
Aberdeen Royal Infirmary in Scotland is 2nd site for P1/2 Clinical Trial Using hESC-Derived RPE Cells for Macular Degeneration Read more…
Investigational Device Exemption (IDE) approval begins the ATHENA trial Read more…
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.